AstraZeneca Pharma India Limited has accepted the resignation of Ms. Bhavana Agrawal from the position of Chief Financial Officer (CFO) and Key Managerial Personnel, effective from the close of business hours on August 31, 2026. The resignation follows her appointment to a regional role within the AstraZeneca Group. The company disclosed this development in a filing submitted to the stock exchanges on July 21, 2026.

Regulatory Disclosures

The announcement was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company provided the necessary details as required under the SEBI Master Circular SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. Tanya Sanish, Company Secretary & Compliance Officer, signed the disclosure on behalf of the company.

Resignation Details

Ms. Bhavana Agrawal communicated her resignation to the Board of Directors on July 20, 2026. In her resignation letter, she expressed gratitude to the Board, senior management, and colleagues for their support during her tenure. The specific details regarding the new regional role or the appointment of a successor were not disclosed in the regulatory filing.

AstraZeneca Pharma India Limited filed its Business Responsibility and Sustainability Report for the financial year 2025-26, disclosing a total turnover of ₹22,755.8 million. The company reported that manufacturing activities at its sole plant were ceased during the year under review. The filing, submitted to the BSE Limited and National Stock Exchange of India Limited, includes an Independent Practitioners’ Limited Assurance Report provided by KPMG Assurance and Consulting Services LLP.

Financial and Operational Overview

The company’s paid-up capital stands at INR 50,000,000. For the financial year 2025-26, export sales contributed ₹1,175.6 million, accounting for 5.2% of the total turnover. The entity operates primarily in the pharmaceuticals sector, with marketing and trading of pharmaceutical products accounting for 90% of its standalone turnover. The reporting boundary for the BRSR is on a standalone basis.

Employee Statistics

As of the end of the financial year, AstraZeneca Pharma India Limited employed 760 permanent employees, comprising 558 male and 202 female workers. The company reported no permanent workers or other than permanent employees on its rolls. The representation of women on the Board of Directors was 83.33%, while women constituted 66.7% of the Key Management Personnel.

Employee Composition

Sustainability and Environmental Impact

The report details the company’s environmental performance, noting that the manufacturing facility underwent decommissioning during the reporting period. Consequently, the company stated it had no specific projects related to reducing greenhouse gas emissions during the year. However, the company maintained mechanisms for Zero Liquid Discharge, where generated effluent is 100% treated in-house and used for landscaping. The organisation confirmed compliance with applicable environmental laws, including conditions from the Karnataka State Pollution Control Board.

Governance and Assurance

The Business Responsibility and Sustainability Report was approved by the Board and covers all nine principles of the National Guidelines on Responsible Business Conduct. Mr. Praveen Rao Akkinepally, Managing Director, oversees the Business Responsibility and Sustainability initiatives. The company obtained limited assurance on the BRSR Core Indicators from KPMG Assurance and Consulting Services LLP.